Type 2 diabetes and weight implications
Type 2 diabetes is a progressive illness, which if not well controlled can lead to damage of the blood vessels, affect eyesight, increase risk of serious health conditions (such as heart attack and stroke) or lead to the development of leg ulcers1.
Remission of Type 2 diabetes is possible through weight loss
New research has shown that it is possible to achieve remission of Type 2
How can OPTIFAST VLCD Program help with weight loss?
The OPTIFAST VLCD Program can help you achieve fast and effective weight loss with a
Weight loss has been shown to help improve health outcomes:
Improve blood glucose control4
Reduce blood cholesterol2
Improve blood pressure control2
Improve quality of life4
Reduce the pain associated with osteoarthritis5
Is OPTIFAST VLCD suitable for people with diabetes?
Most overweight and obese people with Type 1 or Type 2 diabetes can use the OPTIFAST VLCD Program. It is important to speak to your healthcare professional to discuss which level of the Program is most appropriate for you.
OPTIFAST VLCD and diabetes medication
You must consult your doctor or healthcare professional before starting the OPTIFAST VLCD Program, as you may require an adjustment in your medication or insulin dosage, as well as close monitoring of other weight loss markers.
All OPTIFAST VLCD products are low GI
The GI is a ranking of carbohydrates according to their effect on blood glucose levels. ® of GI Symbol Reg. Trademark of Glycemic Index Foundation.
- Burden of Diabetes in Australia: it’s time for more action. University of Sydney, preliminary report, July 2018.
- Anderson, J.W., et al., Importance of Weight Management in Type 2 Diabetes: Review with Metaanalysis of Clinical Studies. Journal of the American College of Nutrition, 2003. 22(5): p. 331-339.
- National Health and Medical Research Council. Clinical practice guidelines for the management of overweight and obesity in adults, adolescents and children in Australia. National Health and Medical Research Council, 2013.
- Lean M.E.J., et al., Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet 2018; 391: 541–51.
- Diabetes UK. DiRECT 2nd Year Findings Press Release. Accessed: 25/7/2019. https://www.directclinicaltrial.org.uk/Documents/DiRECT%202nd%20Year%20Findings%20Press%20Release.pdf